{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:14:52Z","timestamp":1789658092601,"version":"4.0.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["so-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.suronc.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T01:31:19Z","timestamp":1360978279000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues"],"prefix":"10.1016","volume":"22","author":[{"given":"Saleh","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2012.12.002_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.suronc.2012.12.002_bib2","first-page":"1134","article-title":"Biology and management of pancreatic cancer","volume":"56","author":"Ghaneh","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.suronc.2012.12.002_bib3","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2174\/138945012800564086","article-title":"Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas","volume":"13","author":"Wolff","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.suronc.2012.12.002_bib5","first-page":"506571","article-title":"Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer","author":"Tentes","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.suronc.2012.12.002_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.cell.2011.11.060","article-title":"Computational modeling of pancreatic cancer progression reveals dynamics of growth and dissemination and suggests optimum treatment strategies","volume":"148","author":"Haeno","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.suronc.2012.12.002_bib7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Thierry","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suronc.2012.12.002_bib8","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.suronc.2012.12.002_bib9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/07357900701522653","article-title":"Epidermal growth factor receptor-targeted therapy for pancreatic cancer","volume":"25","author":"Papageorgio","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1016\/j.suronc.2012.12.002_bib10","first-page":"151","article-title":"Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization","volume":"18","author":"Dancer","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.suronc.2012.12.002_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nature09460","article-title":"The patterns and dynamics of genomic instability in metastatic pancreatic cancer","volume":"467","author":"Campbell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.suronc.2012.12.002_bib12","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1073\/pnas.0402932101","article-title":"High resolution characterization of the pancreatic cancer","volume":"101","author":"Aguirre","year":"2004","journal-title":"Proc Natl Acad Sci US"},{"key":"10.1016\/j.suronc.2012.12.002_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","article-title":"EGF receptor is required for KRAS-induced pancreatic tumourogenesis","volume":"3","author":"Ardito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.suronc.2012.12.002_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00534-006-1166-5","article-title":"Molecular genetics of pancreatic intraepithelial neoplasia","volume":"14","author":"Feldmann","year":"2007","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.suronc.2012.12.002_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MPA.0b013e318238379d","article-title":"Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma","volume":"41","author":"Handra-Luca","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.suronc.2012.12.002_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","article-title":"Phase III trial of gemcitabine plustipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer","volume":"22","author":"Van Cutsem","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(01)05629-X","article-title":"Antisense therapy in oncology: new hope for an old idea","volume":"358","author":"Tamm","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.suronc.2012.12.002_bib18","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEKinhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib19","volume":"vol. 25","author":"Philip","year":"2007"},{"key":"10.1016\/j.suronc.2012.12.002_bib20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib21","first-page":"470","article-title":"Erlotinib and chemoradiation followed bymaintenance erlotinib for locally advanced pancreatic cancer: a phase I study","volume":"28","author":"Iannitti","year":"2005","journal-title":"Am J Clin Onol"},{"key":"10.1016\/j.suronc.2012.12.002_bib22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0002-9440(10)63485-2","article-title":"BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets","volume":"163","author":"Calhoun","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.4608","article-title":"Sorafenib(S) plus gemcitabine (G) foradvanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium","volume":"25","author":"Wallace","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib24","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/ijc.21532","article-title":"In\u00a0vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer","volume":"18","author":"Ito","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.suronc.2012.12.002_bib25","doi-asserted-by":"crossref","first-page":"23679","DOI":"10.1074\/jbc.M700563200","article-title":"Effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells","volume":"282","author":"Dormond","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.suronc.2012.12.002_bib26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000107356","article-title":"Everolimus chemotherapy, and mycophenolate mofetilsensitize human pancreatic cancer cells to gemcitabine in\u00a0vitro: a novel adjunct to standard","volume":"39","author":"Tuncyurek","year":"2007","journal-title":"Eur Surg Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/annonc\/mdi324","article-title":"PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study","volume":"16","author":"Alberts","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0002-9440(10)64589-0","article-title":"Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with convention","volume":"157","author":"Iacobuzio-Donahue","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","article-title":"The pathology and genetics of metastatic pancreatic cancer","volume":"133","author":"Yachida","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.suronc.2012.12.002_bib30","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio Donahue","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib31","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dp)","volume":"29","author":"Crane","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1349-7006.2005.00071.x","article-title":"Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas","volume":"96","author":"Peng","year":"2005","journal-title":"Cancer Sci"},{"key":"10.1016\/j.suronc.2012.12.002_bib33","doi-asserted-by":"crossref","unstructured":"Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales F A, Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res;27:2291\u20138.","DOI":"10.1093\/nar\/27.11.2291"},{"key":"10.1016\/j.suronc.2012.12.002_bib34","first-page":"8540","article-title":"Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma","volume":"61","author":"Ueki","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib35","first-page":"1850","article-title":"Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions","volume":"33","author":"Neesse","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.suronc.2012.12.002_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molonc.2009.03.004","article-title":"Characterizing DNA methylation patterns in pancreatic cancer genome","volume":"3","author":"Tan","year":"2009","journal-title":"Mol Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bjc.6600734","article-title":"Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions","volume":"88","author":"Klump","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.suronc.2012.12.002_bib38","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/sj.onc.1206582","article-title":"Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma","volume":"22","author":"Dammann","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.suronc.2012.12.002_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5009\/gnl.2008.2.3.137","article-title":"Precursor lesions of pancreatic cancer","volume":"2","author":"Yonezawa","year":"2008","journal-title":"Gut Liver"},{"key":"10.1016\/j.suronc.2012.12.002_bib40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MPA.0b013e31823bcef2","article-title":"Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma","volume":"41","author":"Xia","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.suronc.2012.12.002_bib41","doi-asserted-by":"crossref","first-page":"32905","DOI":"10.1074\/jbc.M200300200","article-title":"Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase\/Akt pathway by homophilic adhesion and actin cytoskeletal organization","volume":"277","author":"Tran","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.suronc.2012.12.002_bib42","doi-asserted-by":"crossref","unstructured":"Zhou W, Liang IC, Yee NS. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development of cancer. Cancer Biol Ther;11:659\u201370.","DOI":"10.4161\/cbt.11.7.14720"},{"key":"10.1016\/j.suronc.2012.12.002_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1535-7163.MCT-04-0186","article-title":"Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines","volume":"4","author":"Garc\u00eda-Morales","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.suronc.2012.12.002_bib44","first-page":"259","article-title":"Combination of proteasome- and histone deacetylase (HDAC) inhibitor treatment of pancreatic cancer","author":"Wray","year":"2008","journal-title":"Gastrointest Cancers Symp"},{"key":"10.1016\/j.suronc.2012.12.002_bib45","article-title":"Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer","author":"Aghdassi","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.suronc.2012.12.002_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cancergencyto.2004.01.032","article-title":"BRCA1 and pancreatic cancer: pedigree findings and their causal relationship","volume":"158","author":"Lynch","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.suronc.2012.12.002_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","article-title":"BRCA2, germline mutations in familial pancreatic carcinoma","volume":"95","author":"Hahn","year":"2003","journal-title":"JNCI"},{"key":"10.1016\/j.suronc.2012.12.002_bib48","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.suronc.2012.12.002_bib49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1078-0432.CCR-05-1048","article-title":"In\u00a0vivo therapeutic responses contingent on Fanconi anemia\/BRCA2 status of the tumour","volume":"11","author":"van der Heijden","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4161\/cbt.4.9.2141","article-title":"BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency","volume":"4","author":"McCabe","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.suronc.2012.12.002_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2009.10.021","article-title":"Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective","volume":"46","author":"Sandhu","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.suronc.2012.12.002_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.suronc.2012.12.002_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2009.11.010","article-title":"MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications","volume":"292","author":"Rachagani","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1016\/j.suronc.2012.12.002_bib54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00268-008-9833-0","article-title":"MicroRNAs, profiling of 95 and analysis, in pancreatic cancer cell lines and surgical specimens by real-time PCR","volume":"33","author":"Zhang","year":"2009","journal-title":"World J Surg"},{"key":"10.1016\/j.suronc.2012.12.002_bib55","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1373\/clinchem.2010.144709","article-title":"The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis","volume":"56","author":"Hanoun","year":"2010","journal-title":"J\u00a0Clin Chem"},{"key":"10.1016\/j.suronc.2012.12.002_bib56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000186051","article-title":"Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer","volume":"9","author":"Lee","year":"2009","journal-title":"Pancreatology"},{"key":"10.1016\/j.suronc.2012.12.002_bib57","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.7.16.6533","article-title":"Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer","volume":"7","author":"Lodygin","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.suronc.2012.12.002_bib58","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1158\/0008-5472.CAN-09-4227","article-title":"Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a\/200b in association with elevated circulating miR-200a and miR-200b levels","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib59","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.surg.2011.06.017","article-title":"MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis","volume":"150","author":"Nakata","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.suronc.2012.12.002_bib60","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","article-title":"MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating L-cells","volume":"4","author":"Ji","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.suronc.2012.12.002_bib61","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/MPA.0b013e3182218ffb","article-title":"Clinical potential of microRNAs in pancreatic ductal adenocarcinoma","volume":"40","author":"Steele","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.suronc.2012.12.002_bib62","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib63","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Hassan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2003.10.012","article-title":"Analysis and microarrays of novel tumor markers in pancreatic and biliary carcinomas using tissue","volume":"35","author":"Swierczynski","year":"2004","journal-title":"Hum Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin immunotherapy targeted cancer","volume":"44","author":"Hassana","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.suronc.2012.12.002_bib66","first-page":"4547","article-title":"Evidence of dishevelled overexpression and transcriptional activity of \u03b2-catenin","volume":"63","author":"Uematsu","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib67","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib68","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.suronc.2012.12.002_bib69","article-title":"Monocytogenes encoding mesothelin for immunotherapy of patients with pancreas and ovarian cancer","author":"Brockstedt","year":"2007","journal-title":"AACR Proc"},{"key":"10.1016\/j.suronc.2012.12.002_bib70","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1245\/s10434-007-9540-3","article-title":"Epithelial\u2013mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer","volume":"14","author":"Javle","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib71","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.humpath.2010.01.016","article-title":"Solitary cell infiltration is a novel indicator of poor prognosis and epithelial\u2013mesenchymal transition in pancreatic cancer","volume":"41","author":"Masugi","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib72","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1177\/002215549904701201","article-title":"SPARC a matricellular glycoprotein with important biological functions","volume":"47","author":"Yan","year":"1999","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.suronc.2012.12.002_bib73","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1038\/sj.onc.1206807","article-title":"SPARC\/osteonectin and interactions is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor\u2013stromal","volume":"22","author":"Sato","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.suronc.2012.12.002_bib74","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib75","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-012-2337-z","article-title":"Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma","author":"Collins","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.suronc.2012.12.002_bib76","unstructured":"Sidney Kimmel. A phase II study of gemcitabine and nab-paclitaxel in combination with GDC-0449. ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/show\/NCT01088815NLMIdentifier:NCT01088815."},{"key":"10.1016\/j.suronc.2012.12.002_bib77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MPA.0b013e31822896dd","article-title":"Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas","volume":"41","author":"Bahra","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.suronc.2012.12.002_bib78","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.ajpath.2011.12.031","article-title":"S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells","volume":"180","author":"Lines","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.suronc.2012.12.002_bib79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.gastro.2009.04.009","article-title":"Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer","volume":"137","author":"Biankin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.suronc.2012.12.002_bib80","article-title":"N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer","author":"Su","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.suronc.2012.12.002_bib81","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-1157-03","article-title":"Comprehensiveanalysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancerincreased expression of matrix metalloproteinase-7 predicts poor survival","volume":"10","author":"Jones","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib82","first-page":"61","article-title":"A\u00a0double blind placebo-controlled randomised study comparing gemcitabine and marimastat withgemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"Br J Cnacer"},{"key":"10.1016\/j.suronc.2012.12.002_bib83","first-page":"2018","article-title":"Overexpression of cyclooxygenase-2 in pancreatic cancer","volume":"5","author":"Okami","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00280-005-0028-1","article-title":"Gemcitabine plus celecoxib (GECO) inadvanced pancreatic cancer: a phase II trial","volume":"57","author":"Ferrari","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.suronc.2012.12.002_bib85","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1172\/JCI42754","article-title":"Inhibiting Cxcr2 disrupts tumor\u2013stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma","volume":"121","author":"Ijichi","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.suronc.2012.12.002_bib86","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yexcr.2011.11.007","article-title":"Stem cells as the root of pancreatic ductal adenocarcinoma","volume":"318","author":"Balic","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.suronc.2012.12.002_bib87","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.bjc.6603437","article-title":"Telomerase peptide vaccination of patients with non-resectable pancreatic cancer, a dose escalating phase I\/II study","volume":"95","author":"Bernhardt","year":"2006","journal-title":"Cancer"}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740412000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740412000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T20:58:19Z","timestamp":1644353899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740412000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0960740412000928"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2012.12.002","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2012.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}